CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 6 No. 3
 

Mammography in One's 40s: Considering the Arguments

By Ann Kelsall | March 1, 1997

Ann Kelsall is a medical writer who reported on the NIH Consensus Development Panel meeting for Oncology News International. Here she considers, from the woman's perspective, the panel's arguments against mammography screening for women ages 40 to 49.

LANDOVER HILLS, Md--The NIH Consensus Development Panel evaluating the value of mammography screening for women ages 40 to 49, concluded their report with a recommendation that women "should have access to the best possible information in an understandable and usable form," so that they can make their own decisions in collaboration with their physician.

Having listened for two days to the debate among experts who agree on little beyond the need for further research, I have to wonder where that crucial information is going to come from for women making decisions here and now.

I am not a physician. My comments on the ongoing debate are personal, based on my own experience as a woman (well beyond my 40s), who has had quite a few mammograms, including two false positives. Suppose I were 40 again. What would I make of the current confusion?

The results of recent randomized controlled trials related to mammography for women between 40 and 49 years old are extremely difficult for the layperson to decipher. All parties do seem to agree, however, that there is some reduction in breast cancer deaths among the women in that age group who are screened. But there is an acerbic parting of the ways when those benefits are evaluated and weighed against the perceived risks.

The Possible Risks

The risks or "harms" to which the panel addressed itself include the inappropriate sense of security that could come with a false-negative reading; the difficulties associated with additional diagnostic testing in the wake of a false positive; the potential risk of overtreatment of low-risk ductal carcinoma in situ (DCIS); and the danger that accompanies exposure to radiation.

The first two issues go to the point that mammography is not perfect. The results can be flat wrong. Not all cancers are detectable by mammography, especially in younger women. It is also true that false positives are not uncommon.

Neither of these possible outcomes seems a valid reason to avoid being tested. Rather they are signals that good advice and follow-up from the physician are crucial. To paraphrase one of the speakers at the panel discussion, should we avoid doing good because we know we cannot achieve perfection?

To be sure, it would be a grave mistake to be lulled into a false sense of security by a favorable test result. And false-positive readings do cause distress. In my own case, the worry occasioned by an abnormal result was ameliorated by my physician's sensitive behavior.

I was notified of the potential problem early in the morning and advised to come for further analysis that same day. On both occasions, the matter was clarified within hours, and I was relieved to hear that all was well. Neither time did it occur to me to stop having mammograms because mine was a little hard to read.

The arguments about inconvenience or "psychosocial consequences" puzzle me greatly. There is about as much inconvenience associated with a mammo-gram as for any physical examination--hardly an argument for avoiding them.

I do understand that early discovery and appropriate treatment of DCIS are matters of much uncertainty. Clearly, more needs to be known about the history of this disease and its treatment.

But if I had the condition myself, the panel's statement that "some cases of DCIS may not progress to invasive cancer," would not comfort me. I would not wish to be ignorant of my condition simply because it might not kill me. For me, the problem would be deciding on appropriate treatment, not on whether I should have had the mammogram.

Radiation exposure is an understandable concern, but, if I am to believe the evidence presented, it is nowhere shown that for the general population or for women of the age in question, that theoretical radiation risk from screening mammography in any way outweighs the known benefit. It has not been shown that any woman has developed breast cancer as a result of mammography. So, assuming that I am dealing with a competent radiologist, the theoretical risk is one I am willing to take.

The panel did recommend that for women in their 40s who choose to have mammography, the costs should be reimbursed by third party payers or HMOs. It is hard to say just how seriously that recommendation will be taken, given the unwillingness of the panel to recommend the test.

My Decision

A woman in her 40s today does not have that "best possible information" called for by the panel. She has to make the best decision she can based on the wild assortment of guidance that is available to her.

In my own case, assuming I were free of symptoms, I suspect my decision could well be based partly on cost. If I were 40 and not sure of coverage, I might well wait, at least until I was 45. After that, I am quite sure that I would be tested, and hope that I was among the great majority for whom age 45 is not too late.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Bladder Cancer Recurrence High, Better Follow-Up Care Needed
  • ASCO: Post-Surgery Surveillance Found Safe in Seminoma
  • Fertility Preservation in Women With Breast Cancer: Challenges and Opportunities
  • Addressing Fertility Concerns in Women Diagnosed With Breast Cancer: Will Serial Reserve Screening Help?
  • Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy